NOVAVAX INC Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net
NOVAVAX INC (NVAX) had Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net of $7.27 million as of 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net
us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet · last filed 2026-02-26
- 2025-12-31: Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net $7.27M.
- 2025-09-30: Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net $7.65M.
- 2025-06-30: Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net $4.68M.
- 2025-03-31: Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net $5.12M.
| Period end | Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net |
|---|---|
| 2025-12-31 | $7.27M 10-K · filed 2026-02-26 |
| 2025-09-30 | $7.65M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $4.68M 10-Q · filed 2025-08-06 |
| 2025-03-31 | $5.12M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $5.57M 10-K · filed 2026-02-26 |
| 2024-09-30 | $5.99M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $6.40M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $6.82M 10-Q · filed 2024-05-10 |
| 2023-12-31 | $7.23M 10-K · filed 2025-02-27 |
| 2023-09-30 | $7.63M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $8.00M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $8.39M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $8.78M 10-K · filed 2024-02-28 |
| 2021-12-31 | $1.54M 10-K · filed 2023-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |